Loss of productivity among commercially insured patients with pulmonary arterial hypertension in the United States
Abstract
This study demonstrates substantial workdays lost due to health services utilization among patients with PAH, further adding to the overall economic burden of PAH. Quantifying productivity loss in PAH patients provides critical insight into the broader societal costs of the disease, supporting the inclusion of indirect costs in future economic evaluations and healthcare policy decisions.
What are the key findings of this study?
Pulmonary arterial hypertension (PAH) affects how much people can work. This study shows that patients with PAH lose many workdays because of their health needs. Understanding this helps everyone see how much PAH costs society, not just in medical bills but in lost work too. It could change how healthcare policies are made! 💔
Key Points
Objective
The research aims to quantify productivity loss among commercially insured patients with pulmonary arterial hypertension (PAH).
Methods
- Analyzed health services utilization data
- Identified workdays lost due to PAH
- Assessed economic implications of productivity losses
Results
- Substantial number of workdays lost due to health issues
- Demonstrated a significant economic burden linked to PAH
- Supported the inclusion of indirect costs in economic evaluations
What is the clinical evidence from this study?
Study Design
Other
Key Finding
Commercially insured patients with pulmonary arterial hypertension experience substantial workdays lost due to health services utilization, adding to the overall economic burden of the disease.